The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

5 Jan 2010 09:00

RNS Number : 0210F
ViaLogy PLC
05 January 2010
 

VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

JANUARY BUSINESS UPDATE

Signs QuantumRD contract with one of US's largest independents

Multiple wells scheduled for Q1

Milestone achieved on University of Texas collaboration site

LondonJanuary 5, 2010ViaLogy (LSE:VIY) ViaLogy announces it is under contract to provide its QuantumRD hydrocarbon reservoir discovery and characterization services to one of the largest privately held Independent Exploration & Production companies in America. Headquartered in Oklahoma, the firm operates internationally and across the United States both onshore and offshore. It currently controls over 4,000 wells. The contract represents an important opportunity for ViaLogy to expand the scope of its QuantumRD technology into new formations. The initial collaboration is focused on discovery and characterization of Pennsylvanian Morrow Sandstone at the Mescalero Springs prospect in Chaves CountyNew Mexico. ViaLogy will analyze 3-D seismic data to discover oil and gas stratigraphic targets with porosity to position wells between 11,000 ft and 12,000 ft depths, and deliver its recommendations in four weeks. The project will further validate QuantumRD's ability to resolve stratigraphic prospects below seismic resolution presently achievable by conventional processing. At the client's request, neither the firm's name nor details of the signed contract will be made public. 

ViaLogy also announces the signing of a contract for QuantumRD with Nordan Oil & Gas Corporation of AbileneTexas, that foresees multiple QuantumRD analysis projects.

These and other new contracts bring ViaLogy's current client base to eight, and its contingent order book of wells to more than 50 (based on the approximate number of drill locations the company expects to provide to clients under signed contracts to date). The company also reports a strong sales pipeline of prospective clients which should extend the use of QuantumRD to an increasing variety of geographical locations and geophysical formations.

The first quarter of 2010 is scheduled to see multiple wells drilled at locations already determined by ViaLogy's QuantumRD analysis. Once the company's recommendations are made, the dates and pace of drilling are decided solely by ViaLogy's clients and depend upon the clients' operational priorities, and such matters as permits, equipment availability, and even weather. In this connection, Atascosa Exploration's planned Escondido well, initially expected at the end of last year, has been delayed until this month due to unexpected lease issues. During the first quarter of this year the two successful wells already identified for Atascosa by ViaLogy will undergo rework to accelerate their production. Their estimates of recoverable barrels of oil remain unchanged. 

ViaLogy's collaboration with another large Texas independent oil and gas exploration company in conjunction with the University of Texas' Bureau of Economic Geology, announced in a July 2009 press release, has concluded an important milestone. Despite previous expert analysis, the chosen site had produced a number of 'dry holes'. ViaLogy's application of QuantumRD to existing data sets has determined new drill location recommendations, and drilling on this challenging 11,000 ft well is slated for the coming weeks. 

ViaLogy's work for Vecta Oil & Gas, announced in September, 2009 and also with the involvement of the Bureau of Economic Geology, has concluded its first phase with the delivery of ViaLogy's QuantumRD analysis and recommended multiple drilling locations. A number of these wells are scheduled for drilling in 2010.

Commenting on the latest New Mexico contract, ViaLogy CEO Robert W. Dean, said, "We are pleased and proud to be working for a company of this firm's stature and experience. They are at the forefront of the industry in applying the most advanced analytical tools, and our hope is to become a mainstay of support in their drilling efforts." On the larger picture regarding QuantumRD, Dean goes on to say "ViaLogy now has a full workload and looks forward to significant business breakthroughs in the coming months, always bearing in mind that we cannot be successful 100 percent of the time."

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGUMAGUPUURA
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.